Biochemistry, Genetics and Molecular Biology
Photodynamics
100%
Vascular Endothelial Growth Factor
85%
Visual Acuity
42%
Randomized Controlled Trial
42%
Lutein
28%
Bevacizumab
28%
Ranibizumab
28%
Clinical Trial
14%
Carbonic Anhydrase Inhibitor
14%
Aflibercept
14%
Beta Blocker
14%
Spironolactone
14%
Medicine and Dentistry
Central Serous Retinopathy
100%
Network Meta-Analysis
100%
Photodynamic Therapy
30%
Vasculotropin
26%
Low Level Laser Therapy
17%
Visual Acuity
13%
Randomized Controlled Trial
13%
Adverse Event
13%
Bevacizumab
8%
Retinal Pigment Epithelium
8%
Xanthophyll
8%
Ranibizumab
8%
Eplerenone
8%
Beta Adrenergic Receptor Blocking Agent
4%
Recurrence Risk
4%
Clinical Trial
4%
Intravitreal Administration
4%
Group Therapy
4%
Nutrition Supplement
4%
Visual Impairment
4%
Photoreceptor
4%
Choroid
4%
Pylorus
4%
Aflibercept
4%
Krypton
4%
Sham Procedure
4%
Carbonate Dehydratase Inhibitor
4%
Spironolactone
4%
Mifepristone
4%
Pharmacology, Toxicology and Pharmaceutical Science
Central Serous Retinopathy
100%
Photodynamic Therapy
30%
Vasculotropin
26%
Adverse Event
13%
Randomized Controlled Trial
13%
Bevacizumab
8%
Xanthophyll
8%
Ranibizumab
8%
Visual Pigment
8%
Eplerenone
8%
Clinical Trial
4%
Beta Adrenergic Receptor Blocking Agent
4%
Recurrence Risk
4%
Intravitreal Administration
4%
Visual Impairment
4%
Aflibercept
4%
Placebo
4%
Carbonate Dehydratase Inhibitor
4%
Nutrition Supplement
4%
Mifepristone
4%
Spironolactone
4%
Krypton
4%
Keyphrases
Micropulse Laser
20%
Half-dose Photodynamic Therapy
4%
Helicobactor Pylori
4%